ABSTRACT
Objective This study examined the host-microbe changes underpinning treatment response to hyperbaric oxygen therapy (HBOT) in ulcerative colitis.
Design Pre- and post-intervention mucosal tissue and fecal samples from two clinical trials, along with fecal samples from healthy controls and fecal and mucosal tissue from disease severity matched UC controls. Mucosal tissue bulk-RNA sequencing, digital spatial profiling (DSP) for single-cell RNA and protein analysis, and immunohistochemistry was performed, in addition to 16S rRNA, shotgun metagenomics, metabolomics, and metaproteomics of fecal samples. Fecal colonization experiments in IL10-/- germ-free mice were performed to confirm observations.
Results Proteomics identified associations between HBOT response status and neutrophil degranulation, with specificity of effect for azurophilic granules. DSP identified a specific HBOT effect on reducing neutrophil STAT3, which was confirmed by immunohistochemistry. HBOT decreased microbial diversity with an accompanying proportional increase in Firmicutes and a secondary bile acid lithocholic acid. The reduction in diversity was due to reductions in mucinophiles, with differences in Akkermansia muciniphila strains being associated with HBOT response status. Proteomics observed an accompanying effect for HBOT on MUC2. Colonization of IL10-/- with stool obtained from HBOT responders resulted in lower colitis activity compared to stool obtained from HBOT non-responders, with no differences in STAT3 expression, suggesting complementary but independent host and microbial responses.
Conclusion HBOT reduces host neutrophil STAT3 and azurophilic granule activity in UC patients, and changes in microbial composition and metabolism in ways that improve colitis activity. Intestinal microbiota, especially strain level variations in A. muciniphila, may contribute to HBOT non-response.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT02144350
Funding Statement
This work was directly supported by an American Gastroenterology Association Research Scholar Award and NIDDK U34 Planning Grant (DK126626) to Parambir S. Dulai. This work was also supported by the Crohns and Colitis Foundation through a Litwin IBD Pioneers Program Grant, the UCSD Collaborative Center for Multiplexed Proteomics, the San Diego Digestive Disease Center (P30 DK120515), UCSD Gastroenterology T32 training grant (DK 0070202; P.S.D., M.T., R.H.M , C.S., and Y.M.), and UCSD Graduate Training Program in Cellular and Molecular Pharmacology (T32 GM007752; LR). Y.M was also supported by an NIH CTSA-funded career-development award (1TL1TR001443). PG is supported by the NIH (UG3TR003355, AI155696 and AI141630). J.T.C. is supported by the NIH (AI123202, AI129973, AI132122, and DK119724). C.G.G. is funded by Institutional Research and Academic Career Development Awards (K12GM068524). C.S. is NIH Training grant (T32, DK007202). K.F. is supported by the NIH (2UL1TR001442-06). B.C. is supported by a Starting Grant from the European Research Council (ERC) under the European Union Horizon 2020 research and innovation program (grant agreement No. ERC-2018-StG- 804135), a Chaire de Excellence from IdEx Universite de Paris (ANR-18-IDEX-0001) an Innovator Award from the Kenneth Rainin Foundation, an ANR grant EMULBIONT ANR-21-CE15-0042-01 and the national program Microbiote from INSERM. P.C.D. is supported by the Crohns and Colitis Foundation (grant #675191).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of UCSD gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosures: None related to the work being presented.
Data Availability
Proteomic data and supplementary files are available online at https://massive.ucsd.edu (Study ID MSV000088636). Metaproteomic data used for the severity-matched patient analyses were derived from a previous study and is available at MassIVE (Study ID MSV000083874). Metabolomics files are available at massive.ucsd.edu (Study ID: MSV000081492 and MSV000086483). Processed 16s, shotgun metagenomic and metabolomic results are available online at qiita.ucsd.edu (Study ID: 11149). Bulk RNA sequencing data is available on NCBI server (accession ID: GSE152229). All results and scripts are available at https://github.com/c6gonzalez/HBOT and https://github.com/rhmills/HBOT_Multiomics. Patient demographics are reported in Supplementary Tables 2 and 3.
